deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT01065662

AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies

A Phase I/IB Study fo AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies

Sponsor: AstraZeneca

Conditions Cervical Cancer Endometrial Cancer Fallopian Tube Cancer Ovarian Cancer Peritoneal Cancer
Interventions cediranib temsirolimus
Updated 11 times since 2017 Last updated: Apr 20, 2021 Started: Feb 28, 2010 Primary completion: Sep 30, 2013 Completion: Mar 31, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01065662, this PHASE1 trial focuses on Cervical Cancer and Endometrial Cancer and remains completed. Sponsored by AstraZeneca, it has been updated 11 times since 2010, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshotActive Not Recruiting~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshotActive Not Recruiting~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshotActive Not Recruiting~Aug 2018 – ~Aug 2019 · 12 months · monthly snapshotActive Not Recruiting~Aug 2019 – ~May 2020 · 9 months · monthly snapshotActive Not Recruiting~May 2020 – ~Jan 2021 · 8 months · monthly snapshotActive Not Recruiting~Jan 2021 – ~May 2021 · 4 months · monthly snapshotActive Not Recruiting~May 2021 – ~Jul 2024 · 38 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. May 2021 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  4. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE1

  5. May 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

▶ Show 6 earlier versions

  1. Aug 2019 — May 2020 [monthly]

    Active Not Recruiting PHASE1

  2. Aug 2018 — Aug 2019 [monthly]

    Active Not Recruiting PHASE1

  3. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE1

  4. Jul 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

  5. Feb 2017 — Jul 2017 [monthly]

    Active Not Recruiting PHASE1

  6. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1

    First recorded

Feb 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • Beth Israel Deaconess Medical Center
  • Massachusetts General Hospital
  • National Comprehensive Cancer Network
  • Susana M. Campos, MD
  • Wyeth is now a wholly owned subsidiary of Pfizer
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations